Le Lézard
Classified in: Health, Covid-19 virus
Subject: MRR

Insights on the Cardiac Arrest Treatment Global Market to 2026 - Rising Healthcare Expenditure in Emerging Countries Presents Opportunities


DUBLIN, Jan. 21, 2022 /PRNewswire/ -- The "Global Cardiac Arrest Treatment Market (2021-2026) by Treatment, Distribution Channel and Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The Global Cardiac Arrest Treatment Market is estimated to be USD 17.63 Bn in 2021 and is expected to reach USD 27.39 Bn by 2026, growing at a CAGR of 9.21%.

The major factor raising the global cardiac arrest treatment market is an increase in cardiovascular disorders (CVDs). The increasingly sedentary lifestyle, high alcohol & tobacco consumption, and rising geriatric population are leading to the increase in CVDs. Furthermore, increasing awareness of cardiac resynchronization therapy devices among the population is escalating the market growth. However, frequent product calls and the high cost of Treatment are anticipated to hinder the market during the forecast period.

Huge investments in research and development associated with cardiac arrest treatment are expected to foster new opportunities for the market during the forecast period.

The Global Cardiac Arrest Treatment Market is segmented based on Treatment, Distribution Channel and Geography.

Company Profiles

Some of the companies covered in this report are Medico S.p.A., Medtronic plc, Novartis AG, Neurescue, Nihon Kohden Corporation, Pfizer, etc.

Competitive Quadrant

The report includes Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Why buy this report?

Key Topics Covered:

1 Report Description

2 Research Methodology

3 Executive Summary
3.1 Introduction
3.2 Market Size and Segmentation
3.3 Market Outlook

4 Market Influencers
4.1 Drivers
4.1.1 Increasing Burden of Cardiovascular Diseases
4.1.2 Increase in Geriatric Population
4.1.3 Growing Awareness of Generic Drugs and Minimal Invasive Procedures
4.1.4 Favorable Reimbursement Policies
4.2 Restraints
4.2.1 Expensive Treatment and Device Replacement Cost
4.3 Opportunities
4.3.1 Technological Advancement
4.3.2 Rising Healthcare Expenditure in Emerging Countries
4.4 Challenges
4.4.1 Lack of Skilled Professionals
4.4.2 Product Recalls
4.5 Trends

5 Market Analysis
5.1 Regulatory Scenario
5.2 Porter's Five Forces Analysis
5.3 Impact of COVID-19
5.4 Ansoff Matrix Analysis

6 Global Cardiac Arrest Treatment Market, By Treatment
6.1 Introduction
6.2 Drugs
6.2.1 Vasopressors
6.2.2 Anti-Arrhythmic Drugs
6.2.3 Anticholinergic Drugs
6.2.4 Corticosteroids
6.2.5 Fibrinolytic Drugs
6.2.6 Beta-Blockers
6.2.7 Others
6.3 Medical Devices
6.3.1 Defibrillators
6.3.1.1 Implantable Cardioverter Defibrillators
6.3.1.2 External Defibrillators
6.3.2 Pacemakers
6.3.2.1 Implantable Pacemakers
6.3.2.2 External Pacemaker
6.3.3 Others

7 Global Cardiac Arrest Treatment Market, By Distribution Channel
7.1 Introduction
7.2 Hospitals
7.3 Retail Pharmacies
7.4 Online Pharmacies
7.5 Others

8 Global Cardiac Arrest Treatment Market, By Geography

9 Competitive Landscape
9.1 Competitive Quadrant
9.2 Market Share Analysis
9.3 Strategic Initiatives
9.3.1 M&A and Investments
9.3.2 Partnerships and Collaborations
9.3.3 Product Developments and Improvements

10 Company Profiles
10.1 Abbott Laboratories
10.2 Amgen Inc
10.3 Allergan
10.4 Bayer AG
10.5 Biotronik SE & Co. KG
10.6 Boston Scientific Corporation
10.7 Bristol Myers Squibb Company
10.8 Fukuda Denshi Co, Ltd
10.9 Koninklijke Philips N.V.
10.10 LivaNova PLC
10.11 Lepu Medical
10.12 MicroPort Scientific Corporation
10.13 Medico S.p.A.
10.14 Medtronic plc
10.15 Novartis AG
10.16 Neurescue
10.17 Nihon Kohden Corporation
10.18 Osypka Medical
10.19 Pfizer Inc
10.20 Sanofi S.A.
10.21 Shree Pacetronix Ltd
10.22 Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
10.23 Stryker Corporation
10.24 Viatris Inc
10.25 ZOLL Medical Corporation

11 Appendix

For more information about this report visit https://www.researchandmarkets.com/r/knbb7c

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]  

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets


These press releases may also interest you

at 18:36
Today, the Public Health Agency of Canada (PHAC) is confirming additional cases of monkeypox in Canada. In addition to the previously reported sixteen confirmed cases in Quebec, PHAC's National Microbiology Laboratory (NML) has confirmed another 10...

at 18:28
Cantargia (Cantargia AB) today reported extended interim results in first-line pancreatic cancer (PDAC) patients treated with nadunolimab (CAN04) in combination with gemcitabine and nab-paclitaxel in the phase I/IIa CANFOUR trial. The efficacy was...

at 18:25
The Seton Hall University School of Health and Medical Sciences joins the Association of Schools Advancing Health Professions (ASAHP) in presenting the 2022 ASAHP Regional Summits on June 3, 2022. For the first time, ASAHP will hold these...

at 18:20
Viemed Healthcare, Inc. (the "Company" or "Viemed") , a home medical equipment supplier and the nation's largest independent provider of ventilation that provides post-acute respiratory care services, announced that it will host a webcast investor...

at 18:20
Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today reported updated interim results for non-small cell lung cancer (NSCLC) patients treated with nadunolimab (CAN04) in combination with gemcitabine and cisplatin, showing efficacy well above...

at 18:00
Ziegler, a specialty investment bank, is pleased to announce its role as exclusive...



News published on 21 january 2022 at 10:00 and distributed by: